Back

Do we need PCSK9 inhibitors in post-MI patients? PRO

27 August 2017 (11:15 - 11:35)
Organised by:
Congress Presentation Part of: Do we need PCSK9 inhibitors in post-MI patients? Drug therapy ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Marc Sabatine

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

7 More presentations in this session

Presentation thumbnail
Opening question.
Slides Video
Presentation thumbnail
Positioning of the topic - The PCSK9 story .. so far
Professor F. Mach (Geneva, CH)
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? CON
Professor H. Drexel (Feldkirch, AT)
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? Rebuttal PRO
Professor M. Sabatine (Boston, US)
Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? Rebuttal CON
Professor H. Drexel (Feldkirch, AT)
Video

Access the full session

Session thumbnail
Do we need PCSK9 inhibitors in post-MI patients?

The Event

Event poster

ESC Congress 2017

27 August 2017 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Early PCSK9 inhibitor subscription during episode of acute myocardial infarction (EPISODE-AMI) study
1 September 2025
thumbnail
Webinar
Reducing risk in the post-MI patient
6 September 2023
thumbnail
Congress Session
The LDL-c challenge in patients with high cardiovascular risk: integrating innovative therapies in clinical management
25 August 2023
thumbnail
Webinar
Acute LDL-C reduction during and immediately after ACS: is it prime time?
7 February 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources